FGF23 and chronic kidney disease: While our results may be specific to the Alport’s model of CKD, they suggest the potential benefit of partially lowering FGF23 in CKD, for example with low or intermediate doses of anti-FGF23 antibodies, even at the cost of a modest increase in serum phosphate, which could be mitigated with concomitant therapies and tested in innovative randomized clinical trials.